Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix provided an operational and financial update, highlighting significant clinical advancements for its lead candidate, NBTXR3. In the Expansion Study 102 involving high-risk, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients, the median overall survival reached 23 months. The company reported €83.9 million in cash as of December 31, 2021, down from €119.2 million in 2020. Revenue for 2021 was only €9.7k compared to €50.0k in 2020. Despite a net loss of €47.0 million, Nanobiotix is advancing multiple pivotal studies in 2022.
Nanobiotix (NASDAQ: NBTX, Euronext: NANO) will report its full-year financial results for December 31, 2021, on March 30, 2022, after market close. The announcement will precede a conference call on March 31, 2022, at 8:00 AM EDT, led by CEO Laurent Levy and CFO Bart Van Rhijn. Investors can submit questions ahead of time via email. The company is advancing its lead oncology product, NBTXR3, currently in clinical trials for head and neck cancer, with strategic collaborations for further development in various cancer types and therapies.
Nanobiotix announced its total outstanding shares as of February 28, 2022, amounting to 34,825,872, with total voting rights listed at 35,999,095 gross and 35,984,023 net. The company, listed on Euronext Paris and NASDAQ under symbol NBTX, focuses on developing innovative therapies targeting cancer and related health issues. With over 30 patents, its lead product NBTXR3 is authorized in Europe for soft tissue sarcoma treatment.
Nanobiotix reported the outstanding shares and voting rights as of January 31, 2021. The company has 34,825,872 shares outstanding, with 36,003,389 total voting rights gross and 35,990,682 total voting rights net. This disclosure complies with the French Commercial Code and the regulations of the French Financial Markets Authority.
Nanobiotix operates in innovative oncology, with its lead product NBTXR3 authorized in Europe for soft tissue sarcoma. The company is listed on both Euronext Paris and NASDAQ under the ticker NBTX.
Nanobiotix has announced a peer-reviewed clinical case study published in Clinical and Translational Radiation Oncology regarding its first-in-human treatment of NBTXR3 for unresectable pancreatic cancer. The study shows the feasibility of local endoscopic delivery with no treatment-related toxicity. Supported by MD Anderson Cancer Center, this phase I trial aims to assess the safety and establish a recommended phase II dose for future efficacy evaluation. The treatment may address unmet needs in managing locally advanced pancreatic cancer.
Nanobiotix announced the publication of new preclinical data for NBTXR3, which shows significant anti-tumor effects in an anti-PD-1 resistant lung cancer model. The study revealed that adding NBTXR3 to a combination of radiotherapy, anti-PD-1, and anti-CTLA-4 improved mouse survival rates from 0% to 50%. Notably, no re-challenged mice developed tumors, indicating a long-term anti-tumor immune memory. The data suggests the potential for further investigations of NBTXR3's immune priming effects in both preclinical and clinical settings.
Nanobiotix (Euronext: NANO, NASDAQ: NBTX) published its regulatory announcement as of December 31, 2021. The report states that there are 34,825,872 outstanding shares and 36,003,389 total voting rights gross. The net voting rights amount to 35,987,933. The figures are in compliance with French Commercial Code and the regulations of the French Financial Markets Authority. The company is developing its lead product candidate, NBTXR3, aiming to transform oncology treatment outcomes.
Nanobiotix has provided a corporate update, highlighting significant advancements with NBTXR3 for treating head and neck cancer. The first European patient has been randomized in the pivotal NANORAY-312 study, with U.S. and Asia site activations expected to follow. The company aims to establish a registration pathway for NBTXR3 in combination with anti-PD-1 therapy based on positive initial data from ongoing studies. Financially, Nanobiotix has extended its operating runway into Q2 2023 through improved operational efficiencies and capital optimization.
Nanobiotix announced the first patient enrollment in the pivotal NANORAY-312 phase III study assessing radiotherapy-activated NBTXR3, with or without cetuximab, for elderly patients with locally advanced head and neck squamous cell carcinoma. This study aims to prove the superiority of NBTXR3 over standard treatments. The US FDA has granted Fast Track designation for NBTXR3 in this patient group, allowing for faster review and potential accelerated approval.
Nanobiotix, a late-stage clinical biotechnology company, announced participation in three virtual investor conferences in January 2022. The events include:
- Oddo BHF Forum 2022: January 6-11, 2022
- H.C. Wainwright Bioconnect Conference: January 10-13, 2022
- Biotech Showcase™ 2022: January 17-19, 2022